CN104116747A - Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof - Google Patents
Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof Download PDFInfo
- Publication number
- CN104116747A CN104116747A CN201410315245.3A CN201410315245A CN104116747A CN 104116747 A CN104116747 A CN 104116747A CN 201410315245 A CN201410315245 A CN 201410315245A CN 104116747 A CN104116747 A CN 104116747A
- Authority
- CN
- China
- Prior art keywords
- parts
- metronidazole
- medicine
- prednisone
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an externally-applied medicine for treating dermatopathy caused by pathogenic fungi, and is characterized in that the externally-applied medicine is prepared from the following medicines in parts by weight: 10-20 parts of a clotrimazole cream, 15-25 parts of a fluocinolone acetonide ointment, 0.6-1.0 part of metronidazole, 1.5-2.0 parts of chloramphenicol, 1-5 parts of borneol, 0.2-0.8 part of a rivanol powder, and 0.05-0.15 part of prednisone. Clinic experiments prove that the externally-applied medicine can safely and effectively treat the dermatopathy caused by the pathogenic fungi.
Description
Technical field
The present invention relates to a kind of external used medicine formula, particularly a kind of external use medicine for treating dermatosis thing that pathogenic fungus causes and preparation method thereof for the treatment of.
Background technology
The common classification of dermatosis and symptom: 1. mycosis: common are trick tinea, tinea corporis and cruris and tinea unguium (tinea unguium); 2. bacterial dermatosis: common are erysipelas and leprosy; 3. viral dermatosis: common are chickenpox, verruca plana and herpes; 4. the dermatosis that arthropod causes: as scabies; 5. sexually transmitted disease (STD): as syphilis, gonorrhea and condyloma acuminatum; 7. physical property dermatosis: common are sunburn, pleiomorphism daylight rash and clavus; 8. delayed ischemic neurological deficits dermatoses: common are the dermatosis that pruritus, neurodermatitis and parasite cause; 9. erythema papulosquamous dermatosis: common are psoriasis, psoriasis, pityriasis simplex and pityriasis rosea; 10. connective tissue disease: common are lupus erythematosus, scleroderma and dermatomyositis; 11. rash dermatoses: common are a day herpes, class sky herpes and palmoplantar pustulosis; 12. pigment obstacle dermatoses: common are chloasma, vitiligo, tattoo; 13. sebums, sweat gland dermatosis: common are acne, rosacea and fetid sweat.Dermatosis is a kind of commonly encountered diseases, frequently-occurring disease clinically, is also the stubborn disease that is difficult to healing.During now treatment is dermopathic, western drug is a lot, the dermatosis causing for pathogenic fungus still lacks the effective medicine of generally recognized as safe at present.
Summary of the invention
The problem to be solved in the present invention is: a kind of dermopathic external used medicine that pathogenic fungus causes for the treatment of is provided, by selecting suitable compound ratio, reaches the dermopathic object that safe and effective healing pathogenic fungus causes.
The present invention is also by the preparation method of the dermopathic external used medicine that provides this treatment pathogenic fungus to cause.
The present invention also will provide the dermopathic external used medicine that this treatment pathogenic fungus causes to select clotrimazole, fluocinolone acetonide, metronidazole, chloromycetin, Borneolum Syntheticum, rivanol powder, prednisone to combine, make each medicine produce synergism, thereby effectively treat the various dermatosiss that pathogenic fungus causes, the consumption of the each crude drug of this medicine is also to have carried out a large amount of practice summaries through applicant to draw, each crude drug consumption all has significant curative effect within the scope of following weight parts:
Clotrimazole cream 10-20 part, fluocinolone acetonide ointment 15-25 part, metronidazole 0.6-1.0 part, chloromycetin 1.5-2.0 part, Borneolum Syntheticum 1-5 part, rivanol powder 0.2-0.8 part, prednisone 0.05-0.15 part.
The best proportioning of each crude drug is counted with weight portion:
15 parts of clotrimazole creams, 20 parts of fluocinolone acetonide ointment, 0.8 part of metronidazole, 1.75 parts, chloromycetin, 3 parts of Borneolum Syntheticums, 0.5 part, rivanol powder, 0.1 part of prednisone.
Below in conjunction with clinical experiment data declaration beneficial effect of the present invention:
1, general material
The dermopathic out-patient that 120 routine pathogenic funguses cause is collected, age 6-60 year, course of disease 1-5 between year August altogether in inventor in June, 2002-2013.Be divided at random: treatment group 80 examples, blank group 40 examples.The data there was no significant differences such as two groups of ages, the state of an illness, have comparability.
2, test method
Matched group is smeared fluocinolone acetonide ointment, uses to specifications.Smear 10 days.
Treatment group is smeared the externally-applied ointment that the present invention makes according to specific embodiment 1, and medicine is directly spread upon to affected part, each
In right amount, every day, general medication 2-3 time, was used in conjunction 10 days.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterion of therapeutical effect
(1) recovery from illness: clinical symptoms and sign disappear completely or substantially disappear;
(2) effective: clinical symptoms and sign are most of to take a turn for the better or is clearly better;
(3) invalid; Clinical symptoms and sign are all not improved, and symptom is as front, DeGrain.
3.2 treatment statistical results are in table 1.
Table 1 liang group curative effect comparison
| Group | Case number | Recovery from illness | Effective | Invalid | Untoward reaction | Total effective rate % |
| Treatment group | 80 | 30 | 46 | 4 | 0(0％) | 95％ |
| Matched group | 40 | 0 | 2 | 38 | 0(0％) | 5％ |
Visible, the medicine that the preferred embodiment for the present invention makes can be treated the dermatosis that pathogenic fungus causes safely and effectively.
Detailed description of the invention
The present invention treats the dermopathic external used medicine that pathogenic fungus causes and can adopt the conventional preparation method of medical external preparation to make various external preparation, take raw material by said ratio, mix homogeneously, adding and preparing different dosage form is the available adjuvant on needed pharmaceutics, prepare adjuvant vaseline, lanoline, paraffin of ointment etc. as added, be prepared into the exterior-applied formulation of the various routines such as ointment, Emulsion, cream, gel, solution, tincture, spray, lotion, liniment by the conventional method of external preparation.
Specific embodiment 1
Get 0.05 gram of 1.5 grams of 0.6 gram of 10 grams of clotrimazole cream, 15 grams of fluocinolone acetonide ointment, metronidazole (every containing 3 of the Metronidazole Tablets of 0.2 gram of metronidazole), chloromycetin (every containing 6 of the Chloramphenicol Tablets of 0.25 gram, chloromycetin), 1 gram of Borneolum Syntheticum, 0.2 gram, rivanol powder, prednisone (every containing 10 of the prednisone sheets of 5 milligrams of prednisones).3 of Metronidazole Tablets, 6 of Chloramphenicol Tablets, 10 of prednisone sheets are ground into fine powder mixs homogeneously with Borneolum Syntheticum, rivanol powder, add 10 grams of clotrimazole creams, 15 grams of fluocinolone acetonide ointment, according to this area ointment common process, make the present invention and treat dermopathic externally-applied ointment.
Specific embodiment 2
Get 0.15 gram of 2.0 grams of 1.0 grams of 20 grams of clotrimazole cream, 25 grams of fluocinolone acetonide ointment, metronidazole (every containing 5 of the Metronidazole Tablets of 0.2 gram of metronidazole), chloromycetin (every containing 8 of the Chloramphenicol Tablets of 0.25 gram, chloromycetin), 5 grams of Borneolum Syntheticums, 0.8 gram, rivanol powder, prednisone (every containing 30 of the prednisone sheets of 5 milligrams of prednisones).5 of Metronidazole Tablets, 8 of Chloramphenicol Tablets, 30 of prednisone sheets are ground into fine powder mixs homogeneously with Borneolum Syntheticum, rivanol powder, add 20 grams of clotrimazole creams, 25 grams of fluocinolone acetonide ointment, according to this area externally applied liniment common process, make the present invention and treat dermopathic externally applied liniment.
Specific embodiment 3
Get 0.1 gram of 1.75 grams of 0.8 gram of 15 grams of clotrimazole cream, 20 grams of fluocinolone acetonide ointment, metronidazole (every containing 4 of the Metronidazole Tablets of 0.2 gram of metronidazole), chloromycetin (every containing 7 of the Chloramphenicol Tablets of 0.25 gram, chloromycetin), 3 grams of Borneolum Syntheticums, 0.5 gram, rivanol powder, prednisone (every containing 20 of the prednisone sheets of 5 milligrams of prednisones).4 of Metronidazole Tablets, 7 of Chloramphenicol Tablets, 20 of prednisone sheets are ground into fine powder mixs homogeneously with Borneolum Syntheticum, rivanol powder, add 15 grams of clotrimazole creams, 20 grams of fluocinolone acetonide ointment, according to this area externally applied spray common process, make the present invention and treat dermopathic externally applied spray.
Facts have proved through a large amount of clinical treatments, the present invention treats the external use medicine for treating dermatosis thing that pathogenic fungus causes, belong to external preparation, little to human body toxicity, side effect, all kinds of dermatosiss that treatment pathogenic fungus is caused have reliably, safe, significant therapeutic effect.
Claims (3)
1. treat the external use medicine for treating dermatosis thing that pathogenic fungus causes, it is characterized in that: it is to be prepared into by the medicine of following parts by weight proportioning: clotrimazole cream 10-20 part, fluocinolone acetonide ointment 15-25 part, metronidazole 0.6-1.0 part, chloromycetin 1.5-2.0 part, Borneolum Syntheticum 1-5 part, rivanol powder 0.2-0.8 part, prednisone 0.05-0.15 part.
2. the external use medicine for treating dermatosis thing that treatment pathogenic fungus according to claim 1 causes, is characterized in that: it is to be prepared into by the medicine of following parts by weight proportioning: 15 parts of clotrimazole creams, 20 parts of fluocinolone acetonide ointment, 0.8 part of metronidazole, 1.75 parts, chloromycetin, 3 parts of Borneolum Syntheticums, 0.5 part, rivanol powder, 0.1 part of prednisone.
3. treat the preparation method of the external use medicine for treating dermatosis thing that pathogenic fungus causes for one kind, it is characterized in that: adopt patent medicine clotrimazole cream, fluocinolone acetonide ointment, Metronidazole Tablet, Chloramphenicol Tablets, prednisone sheet and rivanol powder and Borneolum Syntheticum preparation, every gram of described clotrimazole cream is containing 2 milligrams of clotrimazoles, every gram of fluocinolone acetonide ointment is containing 0.25 milligram of fluocinolone acetonide, every of Metronidazole Tablet contains 0.2 gram of metronidazole, every of Chloramphenicol Tablets contains 0.25 gram, chloromycetin, every of prednisone sheet contains 5 milligrams of prednisones, rivanol powder 0.2-0.8 weight portion, Borneolum Syntheticum 1-5 weight portion, first by Metronidazole Tablet, Chloramphenicol Tablets, prednisone sheet is pulverized, again by even above-mentioned each medicament mixed, obtain finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410315245.3A CN104116747A (en) | 2014-07-03 | 2014-07-03 | Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410315245.3A CN104116747A (en) | 2014-07-03 | 2014-07-03 | Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104116747A true CN104116747A (en) | 2014-10-29 |
Family
ID=51762527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410315245.3A Pending CN104116747A (en) | 2014-07-03 | 2014-07-03 | Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104116747A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524537A (en) * | 2018-06-27 | 2018-09-14 | 赵怀邦 | A kind of scorching only scattered ointment |
| CN110638835A (en) * | 2019-10-24 | 2020-01-03 | 李生林 | External ointment for skin and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1254559A (en) * | 1998-11-25 | 2000-05-31 | 杨大权 | Broad-spectrum antibacterial medicine and its exterior application method |
| CN1429554A (en) * | 2003-01-03 | 2003-07-16 | 徐广春 | Compound beri-beri ointment |
| CN1626244A (en) * | 2004-08-16 | 2005-06-15 | 关中田 | Combination for treating skin disease |
| CN102641375A (en) * | 2012-02-13 | 2012-08-22 | 廖天源 | Medicament for treating tinea capitis, tinea pedis, tinea manuum, onychomycosis, tinea corporis and tinea cruris and preparation method thereof |
-
2014
- 2014-07-03 CN CN201410315245.3A patent/CN104116747A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1254559A (en) * | 1998-11-25 | 2000-05-31 | 杨大权 | Broad-spectrum antibacterial medicine and its exterior application method |
| CN1429554A (en) * | 2003-01-03 | 2003-07-16 | 徐广春 | Compound beri-beri ointment |
| CN1626244A (en) * | 2004-08-16 | 2005-06-15 | 关中田 | Combination for treating skin disease |
| CN102641375A (en) * | 2012-02-13 | 2012-08-22 | 廖天源 | Medicament for treating tinea capitis, tinea pedis, tinea manuum, onychomycosis, tinea corporis and tinea cruris and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 彭军等: "MCCT搽剂的制备与临床疗效观察", 《中国医院药学杂志》, vol. 11, no. 10, 31 December 1991 (1991-12-31), pages 473 - 474 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524537A (en) * | 2018-06-27 | 2018-09-14 | 赵怀邦 | A kind of scorching only scattered ointment |
| CN110638835A (en) * | 2019-10-24 | 2020-01-03 | 李生林 | External ointment for skin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103908473B (en) | Treat and prevent the application of the nanometer silver anti-cancer composition of uterus neck cancer | |
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| CN101843637B (en) | External spray for preventing and treating beriberi and preparation method | |
| WO2014059880A1 (en) | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation | |
| PL188153B1 (en) | Drug and manner of exterting a pharmacological effect on human organism by such drug | |
| CN104116747A (en) | Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof | |
| CN101152546B (en) | Externally used preparations with functions of anti-inflammation, relieving itching and sterilization disinfection, and method for preparing the same | |
| HUE025475T2 (en) | Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith | |
| CN112274509B (en) | Application of xidabenamine and BCL2 inhibitor in double-expression B cell lymphoma | |
| CN101961348A (en) | Fute panacea | |
| CN103251636A (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| CN104815103A (en) | Toxin removal powder | |
| CN102274238B (en) | Pharmaceutical composition for treating pancreatic cancer | |
| CN102258526B (en) | Anticancer medicinal composition | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN102415953A (en) | Deodorizing medicinal cosmetic and preparation method thereof | |
| CN102973577B (en) | Compound sodium sulfaquinoxaline composition for treating coccidiosis in young rabbits, and preparation method thereof | |
| CN102784166B (en) | The compound ivermectin composition and method of making the same for the treatment of domestic animal acariasis | |
| CN102727515A (en) | Medicinal preparation for treating dermatophytosis | |
| CN104490905B (en) | A kind of emulsifiable paste and preparation method for being used to treat hemorrhoid | |
| CN102240298B (en) | Pharmaceutical composition for resisting tumors | |
| US20150079054A1 (en) | Compositions and methods for treatment of pain | |
| CN104107224B (en) | A kind of medical composition and its use treating senile skin pruritus | |
| US20170319475A1 (en) | Medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, preparation method therefor and use method thereof | |
| Haghi et al. | Review of Anti-Infective Activity of Boric Acid: A Promising Therapeutic Approach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141029 |